The identical director sales signal a possible secondary offering or lockup expiration, watch for an S-1 filing or 8-K disclosure. Monitor for any concurrent corporate filings.
SION drugs
SION drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 8 $44.00entry
- T+1 · 4mo ago +2.14%α +1.29% · $44.94
- T+5 · 4mo ago −3.20%α −4.07% · $42.59
- T+20 · 3mo ago +7.59%α +4.32% · $47.34
- T+60 · 7w ago −88.41%α −90.90% · $5.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three Sionna Therapeutics insiders sold a combined $10.99M in shares over a 7-day window, including two directors who each sold $5.27M at $45.50. The total represents 0.58% of the $1.9B market cap. While insider selling is a weaker signal than buying, the identical size and timing of the director sales suggest a planned distribution, potentially a secondary offering or lockup expiration.
Key Financial Metrics
Key Facts
- Total insider sales of $10.99M over 7 days, or ~0.58% of market cap
- OrbiMed Advisors LLC (Director) sold 115.8K shares at $45.50 for $5.27M on 2026-06-30
- Director Peter A. Thompson sold 115.8K shares at $45.50 for $5.27M on 2026-06-30
- Chief Legal Officer Jennifer Fitzpatrick sold 10.3K shares at $43.60 for $447K on 2026-07-06, following option exercises
Financial Impact
Insider sales totaling $10.99M, equivalent to 0.58% of market cap
Risk Factors
- Further insider selling or a registered secondary offering could increase supply
- The CLO's sale after option exercise is routine, but two directors selling identical amounts raises the risk of a block trade
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SION-1783456867164 |
Track record
22 reports on SION
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
- Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
- Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
- Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
- Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
- Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
- Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers